Melanoma

Dr. Mario Sznol is a Professor of Medicine (Medical Oncology). Dr. Sznol, formerly with the National Cancer Institute, has an international reputation in cancer drug development. Dr. Sznol's expertise and experience is in cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is working to expand the opportunities for clinical trials at the Yale Cancer Center, particularly those focusing on immunotherapy and novel agents.Learn more about Dr. Mario Sznol>>

Marcus Bosenberg MD, PhD, is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Cancer Immunology Program of Yale Cancer Center, Director of the Yale Center for Immuno-Oncology, Contact PI of the Yale SPORE in Skin Cancer,  Director of the Center for Precision Cancer Modeling, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.In his research, Dr. Bosenberg studies factors that regulate anti-cancer immune responses. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new cancer therapies, and how the immune system can be stimulated to fight cancer. He works to translate basic scientific findings into improvements in cancer diagnosis and therapy. He has published over 200 peer-reviewed articles and is a member of the Yale Cancer Center Executive Committee.Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.

David Braun, MD, PhD, is an Assistant Professor of Medicine (Medical Oncology) and a member of the Center of Molecular and Cellular Oncology (CMCO) at Yale Cancer Center. Dr. Braun cares for patients with kidney cancers. He received his PhD in Computational Biology from the Courant Institute of Mathematical Science at New York University and his medical degree from Icahn School of Medicine at Mount Sinai. He completed his residency at the Brigham and Women’s Hospital where he received the Dunn Medical Intern Award and served as Chief Medical Resident before completing fellowship training in adult oncology through the Dana-Farber/Partners CancerCare program where he was appointed the Emil Frei Fellow and the John R. Svenson Fellow. Dr. Braun joined Yale from Dana-Farber Cancer Institute where he was an Instructor in Medicine with clinical and scientific interest in understanding and improving immune therapies for kidney cancer. He has a longstanding interest in integrating experimental and computational approaches to biomedical research and is currently studying mechanisms of response and resistance to immune therapy in kidney cancer, with the goal of developing novel therapies. He continues this work as part of the CMCO, which fosters and mentors physician-scientists as they advance their laboratory-based research programs to bridge fundamental cancer biology with clinical investigation for the translation of basic discoveries into better treatments or diagnosis.

Dr. Mike Hurwitz is an Associate Professor of Medicine (Medical Oncology). For over 20 years, he has specialized in treating patients with cancers of the genitourinary tract (kidney, bladder, prostate and testicular cancers) and, more recently, in using immune cell-based therapies to treat a large range of solid tumor cancers. His main research efforts are to expand the availability of trials of cell-based therapies to patients with solid tumors.

Dr. Ishizuka is a medical oncologist who treats melanoma patients and Principal Investigator of the Ishizuka Lab. His laboratory studies the tumor-immune microenvironment and seeks to uncover novel approaches by which inflammation can be manipulated to improve cancer immunotherapies.

Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis. Please visit the lab website at: https://sites.google.com/yale.... Learn more about Dr. Kluger>>

Dr. Mario Sznol is a Professor of Medicine (Medical Oncology). Dr. Sznol, formerly with the National Cancer Institute, has an international reputation in cancer drug development. Dr. Sznol's expertise and experience is in cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is working to expand the opportunities for clinical trials at the Yale Cancer Center, particularly those focusing on immunotherapy and novel agents.Learn more about Dr. Mario Sznol>>

Dr. Tran is an Assistant Professor of Medicine (Medical Oncology) and cares for patients with melanoma and other advanced skin cancers at the Smilow Cancer Hospital in New Haven and in Smilow Guilford. She participated in the ABIM Physician-Scientist Research Pathway and completed both her internal medicine residency and hematology/oncology clinical fellowship at Yale.  She received her MD and PhD degrees from Vanderbilt University School of Medicine.  Dr. Tran is actively engaged in translational research in melanoma brain metastases and developing novel therapeutics and drug combinations to improve responses in melanoma and overcome immune resistance.  She has been funded through the Yale Cancer Center T32, the YCC K12 Calabresi Immuno-Oncology Training Program (IOTP), and the Skin Cancer SPORE career enhancement program.  Dr. Tran is the principal investigator of several clinical trials in melanoma.